Y-mAbs Therapeutics, Inc. (YMAB)
Market Cap | 649.65M |
Revenue (ttm) | 84.82M |
Net Income (ttm) | -21.43M |
Shares Out | 43.78M |
EPS (ttm) | -0.49 |
PE Ratio | n/a |
Forward PE | 119.05 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 349,345 |
Open | 15.33 |
Previous Close | 15.29 |
Day's Range | 14.28 - 15.46 |
52-Week Range | 4.60 - 20.90 |
Beta | 0.76 |
Analysts | Buy |
Price Target | 15.86 (+6.87%) |
Earnings Date | May 6, 2024 |
About YMAB
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line r... [Read more]
Financial Performance
In 2023, YMAB's revenue was $84.82 million, an increase of 29.96% compared to the previous year's $65.27 million. Losses were -$21.43 million, -77.58% less than in 2022.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for YMAB stock is "Buy." The 12-month stock price forecast is $15.86, which is an increase of 6.87% from the latest price.
News
Y-mAbs to Present at 2024 ASCO Annual Meeting
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercia...
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer
NEW YORK, March 14, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercia...
Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors
Dr. Tagliaferri brings deep biopharmaceutical industry expertise and a successful track record in oncology therapeutic development Dr. Tagliaferri brings deep biopharmaceutical industry expertise and ...
Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
NEW YORK, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercial...
Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024
NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter and full year...
Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercial...
Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index
NEW YORK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercial...
Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023
NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the third quarter ended S...
Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director
NEW YORK, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercial...
Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA
Clearance of CD38-SADA IND marks the second clinical development program utilizing the Company's novel SADA technology platform Clearance of CD38-SADA IND marks the second clinical development program...
Y-mAbs Announces Publication in Cancers
Naxitamab-based chemo-immunotherapy significantly improves long-term outcomes when administered early during the course of treatment Naxitamab-based chemo-immunotherapy significantly improves long-ter...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Y-mAbs Therapeutics Inc. (NASDAQ: YMAB)
NEW YORK , Sept. 21, 2023 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Y-mAbs Therapeutics Inc. (NASDAQ: YMAB) concerning possible breaches of fiduciary duty.
Y-mAbs Announces Data to be Presented at the 55th Congress of the International Society of Pediatric Oncology
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercia...
Y-mAbs to Participate at Upcoming Investor Conferences in September
NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercia...
Y-mAbs to Participate at Upcoming Investor Conferences
NEW YORK, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercial...
Y-mAbs to Announce Second Quarter 2023 Financial and Operating Results on August 10, 2023
NEW YORK, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the second quarter ended ...
Y-mAbs Announces Presentation of Naxitamab Data at ASCO
NEW YORK, May 26, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializ...
Y-mAbs Announces Presentation of GD2-SADA Study at ASCO
NEW YORK, May 26, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializ...
Y-mAbs' DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in Brazil
NEW YORK, May 23, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializ...
Y-mAbs Reports First Quarter 2023 Financial Results and Recent Corporate Developments and Updates 2023 Financial Guidance
NEW YORK, May 08, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializ...
Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023
NEW YORK, April 28, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended March ...
Y-mAbs Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments
NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercial...
Y-mAbs to Announce 2022 Financial and Operating Results on March 30, 2023
NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for year ended December 31, ...
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Y-mAbs Investors of a Lead Plaintiff Deadline of March 20, 2023
NEW YORK , March 20, 2023 /PRNewswire/ -- Attention Y-mAbs Therapeutics, Inc. ("Y-mAbs") (NASDAQ: YMAB) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced...
Y-MABS INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Y-mAbs To Contact Him Directly To Discuss Their Options
NEW YORK , March 18, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") ...